


2025 American Society of Clinical Oncology (ASCO) Annual Meeting



 Monday, June 2, 2025

 9:00am CDT

Title: HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥ 20

Lead Author: Jong Chul Park

Abstract: TPS6109

Poster presentation: Monday, June 2, 2025



[ASCO 2025 HexAgon-HN TIP](#)

(3 MB)

<https://inhibrxbiosciences.investorroom.com/events-and-presentations?item=48>